TY - JOUR
T1 - Early-stage diffuse large B cell lymphoma of the head and neck
T2 - Clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
AU - Mian, M.
AU - Capello, D.
AU - Ventre, M. B.
AU - Grazio, D.
AU - Svaldi, M.
AU - Rossi, A.
AU - Tsang, R.
AU - Gospodarowicz, M. K.
AU - Oldani, E.
AU - Federico, M.
AU - Luminari, S.
AU - Marcheselli, L.
AU - Pogliani, E. M.
AU - Rossini, F.
AU - Cabrera, M. E.
AU - Martelli, M.
AU - Gutierrez-Garcia, G.
AU - Busetto, M.
AU - Visco, C.
AU - Fiegl, M.
AU - Rossi, D.
AU - Gaidano, G.
AU - Cavalli, F.
AU - Zucca, E.
AU - Rambaldi, A.
AU - Cortelazzo, S.
N1 - Funding Information:
Acknowledgments The authors thank Andrés J.M. Ferreri, Annarita Conconi, Monica Bellei and Armando López-Guillermo for their support. This work was supported by the Autonomous Province of Bolzano, the local health authority and Alto Adige Bolzano-AIL “Mirco Federici” Onlus.
PY - 2014/2
Y1 - 2014/2
N2 - It is known that extranodal head and neck diffuse large B cell lymphomas (eHN-DLBCL) can affect various anatomical structures what is not well-known, however, is whether they differ in terms of clinical presentation and outcome. Clinical data of the multi-institutional series, the largest of its kind as yet, has been analysed with the aim of answering these open questions and providing long-term follow-up information. Data from 488 patients affected by stage I/II eHN-DLBCL was collected: 300 of the Waldeyer's Ring (WR), 38 of the parotid and salivary glands (PSG), 48 of the thyroid gland (TG), 53 of the nasal cavity and paranasal sinuses (NPS), 24 of the palate and oral cavity (POC) and 25 with more than one involved site. Different eHN-DLBCL arising have distinct characteristics at presentation. The intermediate high risk-modified IPI was 67 % in TG, 44 % in WR, 38 % in PSG and POC and 20 % in MS. The worst 5-year survival rate had TG-DLBCL (61 %) due to the 61 % of patients with a mIPI >1. The addition of radiotherapy (cRT) to remitters did not translate into a survival advantage (5-year disease-free survival of 67 % in the cRT group vs. 70 % in the other). Three of four central nervous system recurrences occurred in NPS-DLBCL. Survival of HN-DLBCL was inferior to nodal DLBCL. This study showed that eHN-DLBCL remitters have an inferior survival when compared to nodal DLBCL, and that the addition of cRT does not provide a survival advantage. Since the standard of care nowadays is chemo-immunotherapy, survival of these patients might have been improved.
AB - It is known that extranodal head and neck diffuse large B cell lymphomas (eHN-DLBCL) can affect various anatomical structures what is not well-known, however, is whether they differ in terms of clinical presentation and outcome. Clinical data of the multi-institutional series, the largest of its kind as yet, has been analysed with the aim of answering these open questions and providing long-term follow-up information. Data from 488 patients affected by stage I/II eHN-DLBCL was collected: 300 of the Waldeyer's Ring (WR), 38 of the parotid and salivary glands (PSG), 48 of the thyroid gland (TG), 53 of the nasal cavity and paranasal sinuses (NPS), 24 of the palate and oral cavity (POC) and 25 with more than one involved site. Different eHN-DLBCL arising have distinct characteristics at presentation. The intermediate high risk-modified IPI was 67 % in TG, 44 % in WR, 38 % in PSG and POC and 20 % in MS. The worst 5-year survival rate had TG-DLBCL (61 %) due to the 61 % of patients with a mIPI >1. The addition of radiotherapy (cRT) to remitters did not translate into a survival advantage (5-year disease-free survival of 67 % in the cRT group vs. 70 % in the other). Three of four central nervous system recurrences occurred in NPS-DLBCL. Survival of HN-DLBCL was inferior to nodal DLBCL. This study showed that eHN-DLBCL remitters have an inferior survival when compared to nodal DLBCL, and that the addition of cRT does not provide a survival advantage. Since the standard of care nowadays is chemo-immunotherapy, survival of these patients might have been improved.
KW - DLBCL
KW - Extranodal
KW - Head
KW - Lymphoma
KW - Neck
UR - http://www.scopus.com/inward/record.url?scp=84895062376&partnerID=8YFLogxK
U2 - 10.1007/s00277-013-1856-4
DO - 10.1007/s00277-013-1856-4
M3 - Article
SN - 0939-5555
VL - 93
SP - 221
EP - 231
JO - Annals of Hematology
JF - Annals of Hematology
IS - 2
ER -